Allmed Medical Products Co (002950) Fair Value & Analysis
Healthcare · CN · Market cap 5.8B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥12.21 to ¥8.65 (−29.2%) since Jun 25, 2026. Share price +5.6% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥6.48 (bear) to ¥10.81 (bull), base ¥8.65. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 68/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥6.17 – ¥20.57 · fair‑value band ¥6.48 – ¥10.81 · the ¥9.43 price screens above the ¥8.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Allmed Medical Products Co (002950) currently trades at ¥9.43, while our model-based Fair Value estimate is ¥8.65, implying the stock looks roughly 8.3% fairly valued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Allmed Medical Products Co generated revenue of 3.8B CNY at a net margin of 7.1%. Revenue grew 18.1% year over year. It earns a return on equity of 7.8%. The balance sheet holds a net cash position of 1.2M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥6.48 (bear case) to ¥10.81 (bull case); at ¥9.43, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -8%, 002950 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth DCF (¥15.02) versus Dividend Discount (¥1.25). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Allmed Medical Products Co.,Ltd manufactures and sells wound care and nursing material products in China. The company's traditional wound care products include non-woven and woven gauze swabs, non-adherent pads, drain sponges, abdominal pads, fluffy sponges/bandages, woven gauze and nonwoven gauze balls, eye pads, cotton-filled exodontia sponges, packing …
Full company description
Allmed Medical Products Co.,Ltd manufactures and sells wound care and nursing material products in China. The company's traditional wound care products include non-woven and woven gauze swabs, non-adherent pads, drain sponges, abdominal pads, fluffy sponges/bandages, woven gauze and nonwoven gauze balls, eye pads, cotton-filled exodontia sponges, packing strips, ribbon gauze, cotton-tipped applicators, elastic net bandages, nose bandages, instrument covers, impregnated gauze dressings, adhesive dressings and tapes, wound bandages, kits, and precut gamgee. Its advanced wound care products consist of hydrocolloid dressings, hydrocolloid bandages, blister dressings, silicone foam dressings, superabsorbent dressings, silicone scar patches, and alginate dressings. OR consumables include x-ray woven gauze/nonwoven gauze swabs and balls, neuro and laparotomy sponges, OR towels, and disposable towel drapes. In addition, the company offers SMS fabric, sterilization wraps, surgical gowns, drapes, surgical packs, normal isolation gowns, isolation gowns (various levels), masks, surgical caps, shoe covers, and boot covers. Allmed Medical Products Co.,Ltd was founded in 1997 and is based in Shenzhen, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Allmed Medical Products Co reported revenue of ¥3.7B in FY2025 versus ¥2.9B in FY2021, a compound +5.8%/yr. Reported net income was ¥249M in FY2025, compounding −12.8%/yr from FY2021.
Watch 002950: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Allmed Medical Products Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Allmed Medical Products Co (002950) overvalued or undervalued?
What is the fair value of 002950?
What is the quality score of 002950?
What is the revenue of Allmed Medical Products Co (002950)?
What is the net profit margin of 002950?
Does Allmed Medical Products Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Allmed Medical Products Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.